
Gossamer Bio Secures $250 Million Funding to Advance Seralutinib Development
Gossamer Bio has secured a private placement agreement worth up to $250 million, with $150 million committed to advancing the development and potential FDA approval of seralutinib. This funding announcement could have implications for American pharmaceutical innovation and the future availability of new treatments in the industry.












